Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Nov. 06, 2020 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000834365 | |
Entity Registrant Name | BIOLIFE SOLUTIONS INC | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2020 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2020 | |
Document Transition Report | false | |
Entity File Number | 001-36362 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-3076866 | |
Entity Address, Address Line One | 3303 Monte Villa Parkway, Suite 310 | |
Entity Address, City or Town | Bothell | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 98021 | |
City Area Code | 425 | |
Local Phone Number | 402-1400 | |
Title of 12(b) Security | BioLife Solutions, Inc. Common Shares | |
Trading Symbol | BLFS | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 32,735,912 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Current assets | ||
Cash and cash equivalents | $ 93,984 | $ 6,448 |
Restricted cash in escrow | 15,000 | |
Accounts receivable, trade, net | 6,095 | 5,345 |
Inventories | 11,037 | 10,972 |
Prepaid expenses and other current assets | 1,668 | 1,348 |
Total current assets | 127,784 | 24,113 |
Assets held for rent, net | 5,131 | 3,922 |
Property and equipment, net | 5,300 | 5,572 |
Operating lease right-of-use assets, net | 585 | 1,040 |
Long-term deposits and other assets | 35 | 50 |
Investments | 3,610 | 2,500 |
Accrued interest receivable | 54 | |
Intangible assets, net | 19,882 | 21,982 |
Goodwill | 33,506 | 33,637 |
Total assets | 195,887 | 92,816 |
Current liabilities | ||
Accounts payable | 2,355 | 3,119 |
Accrued expenses and other current liabilities | 3,364 | 3,369 |
Lease liabilities, operating, current portion | 729 | 804 |
Contingent consideration, current portion | 377 | |
Warrant liability, current portion | 1,914 | |
Total current liabilities | 8,362 | 7,669 |
Warrant liability, long-term | 39,602 | |
Contingent consideration, long-term | 386 | 1,537 |
Lease liabilities, operating, long-term | 26 | 550 |
Other long-term liabilities | 262 | 4 |
Total liabilities | 9,036 | 49,362 |
Commitments and Contingencies (Note 11) | ||
Shareholders’ equity | ||
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively | 0 | 0 |
Common stock, $0.001 par value; 150,000,000 shares authorized, 32,131,165 and 20,825,452 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively | 32 | 21 |
Additional paid-in capital | 282,076 | 143,485 |
Accumulated deficit | (95,257) | (100,052) |
Total shareholders’ equity | 186,851 | 43,454 |
Total liabilities and shareholders’ equity | $ 195,887 | $ 92,816 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2020 | Dec. 31, 2019 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 150,000,000 | 150,000,000 |
Common stock, issued (in shares) | 32,131,165 | 20,825,452 |
Common stock, outstanding (in shares) | 32,131,165 | 20,825,452 |
Series A Preferred Stock [Member] | ||
Preferred stock, shares designated (in shares) | 4,250 | 4,250 |
Preferred stock, issued (in shares) | 0 | 0 |
Preferred stock, outstanding (in shares) | 0 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Revenue | $ 11,279,000 | $ 6,604,000 | $ 33,361,000 | $ 19,075,000 |
Operating expenses | ||||
Cost of product and rental revenue (exclusive of intangible assets amortization) | 4,826,000 | 2,094,000 | 13,893,000 | 5,710,000 |
Research and development | 1,725,000 | 1,032,000 | 4,865,000 | 2,082,000 |
Sales and marketing | 1,588,000 | 1,250,000 | 4,530,000 | 3,032,000 |
General and administrative | 3,503,000 | 2,348,000 | 9,916,000 | 6,707,000 |
Intangible assets amortization | 706,000 | 361,000 | 2,100,000 | 465,000 |
Acquisition costs | 179,000 | 291,000 | 417,000 | 538,000 |
Change in fair value of contingent consideration | (2,000) | (1,528,000) | 0 | |
Total operating expenses | 12,525,000 | 7,376,000 | 34,193,000 | 18,534,000 |
Operating income (loss) | (1,246,000) | (772,000) | (832,000) | 541,000 |
Other income (expense) | ||||
Change in fair value of warrant liability | (1,005,000) | 1,128,000 | 4,467,000 | (14,949,000) |
Change in fair value of investments | 1,110,000 | 0 | 1,110,000 | 0 |
Interest income | 16,000 | 110,000 | 63,000 | 417,000 |
Interest expense | (3,000) | (1,000) | (4,000) | (5,000) |
Other expense | (5,000) | (13,000) | (9,000) | (13,000) |
Loss from equity method investment in SAVSU | (291,000) | 0 | (739,000) | |
Gain on Acquisition of SAVSU | 0 | 10,108,000 | 0 | 10,108,000 |
Total other income (expenses) | 113,000 | 11,041,000 | 5,627,000 | (5,181,000) |
Net income (loss) before provision for income taxes | (1,133,000) | 10,269,000 | 4,795,000 | (4,640,000) |
Income tax (benefit) | 0 | 0 | 0 | 0 |
Net income (loss) | (1,133,000) | 10,269,000 | 4,795,000 | (4,640,000) |
Net income attributable to common stockholders: | ||||
Basic | (1,133,000) | 8,380,000 | 4,322,000 | (4,640,000) |
Diluted | $ (1,133,000) | $ 8,862,000 | $ 279,000 | $ (4,640,000) |
Earnings per share attributable to common stockholders | ||||
Basic (in dollars per share) | $ (0.04) | $ 0.42 | $ 0.17 | $ (0.24) |
Diluted (in dollars per share) | $ (0.04) | $ 0.35 | $ 0.01 | $ (0.24) |
Weighted average shares used to compute earnings per share attributable to common stockholders: | ||||
Basic (in shares) | 31,639,420 | 19,735,364 | 25,418,375 | 19,071,722 |
Diluted (in shares) | 31,639,420 | 25,343,112 | 29,412,538 | 19,071,722 |
Product [Member] | ||||
Revenue | $ 10,804,000 | $ 6,422,000 | $ 32,020,000 | $ 18,864,000 |
Rental Revenue [Member] | ||||
Revenue | $ 475,000 | $ 182,000 | $ 1,341,000 | $ 211,000 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands | Preferred Stock [Member]Series A Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 0 | 18,547,406 | |||
Balance at Dec. 31, 2018 | $ 0 | $ 19 | $ 113,008 | $ (98,395) | $ 14,632 |
Stock-based compensation | $ 0 | $ 0 | 2,179 | 0 | 2,179 |
Stock option exercises (in shares) | 0 | 474,237 | |||
Stock option exercises | $ 0 | $ 0 | 841 | 0 | 841 |
Warrant exercises (in shares) | 116,500 | ||||
Warrant exercises | $ 0 | 2,247 | 0 | 2,247 | |
Stock issued – on vested RSUs (in shares) | 0 | 106,682 | |||
Stock issued – on vested RSUs | $ 0 | $ 0 | 0 | 0 | 0 |
Net income | $ 0 | $ 0 | 0 | (4,640) | (4,640) |
Shares issued as consideration in SAVSU acquisition (in shares) | 1,100,000 | ||||
Shares issued as consideration in SAVSU acquisition | $ 1 | 19,931 | 0 | 19,932 | |
Balance (in shares) at Sep. 30, 2019 | 0 | 20,344,825 | |||
Balance at Sep. 30, 2019 | $ 0 | $ 20 | 138,206 | (103,035) | 35,191 |
Balance (in shares) at Jun. 30, 2019 | 0 | 18,898,609 | |||
Balance at Jun. 30, 2019 | $ 0 | $ 19 | 115,357 | (113,304) | 2,072 |
Stock-based compensation | $ 0 | $ 0 | 829 | 0 | 829 |
Stock option exercises (in shares) | 0 | 238,176 | |||
Stock option exercises | $ 0 | $ 0 | 378 | 0 | 378 |
Warrant exercises (in shares) | 87,500 | ||||
Warrant exercises | $ 0 | 1,711 | 0 | 1,711 | |
Stock issued – on vested RSUs (in shares) | 0 | 20,540 | |||
Stock issued – on vested RSUs | $ 0 | $ 0 | 0 | 0 | 0 |
Net income | $ 0 | $ 0 | 0 | 10,269 | 10,269 |
Shares issued as consideration in SAVSU acquisition (in shares) | 0 | 1,100,000 | |||
Shares issued as consideration in SAVSU acquisition | $ 0 | $ 1 | 19,931 | 0 | 19,932 |
Balance (in shares) at Sep. 30, 2019 | 0 | 20,344,825 | |||
Balance at Sep. 30, 2019 | $ 0 | $ 20 | 138,206 | (103,035) | 35,191 |
Balance (in shares) at Dec. 31, 2019 | 0 | 20,825,452 | |||
Balance at Dec. 31, 2019 | $ 0 | $ 21 | 143,485 | (100,052) | 43,454 |
Stock issued as 2019 bonus payout | $ 0 | $ 0 | 314 | 0 | 314 |
Sale of common stock, net of costs (in shares) | 0 | 7,856,012 | |||
Sale of common stock, net of costs | $ 0 | $ 8 | 100,113 | 0 | 100,121 |
Common stock issued for services (in shares) | 3,175 | ||||
Common stock issued for services | $ 0 | 60 | 0 | 60 | |
Stock-based compensation | $ 0 | $ 0 | 3,818 | 0 | 3,818 |
Stock option exercises (in shares) | 0 | 528,793 | |||
Stock option exercises | $ 0 | $ 0 | 1,028 | 0 | 1,028 |
Cashless exercises of 3,871,405 warrants (in shares) | 0 | 2,747,970 | |||
Cashless exercises of warrants | $ 0 | $ 3 | 33,108 | 0 | 33,111 |
Warrant exercises (in shares) | 8,500 | ||||
Warrant exercises | $ 0 | 150 | 0 | 150 | |
Stock issued – on vested RSUs (in shares) | 0 | 161,263 | |||
Stock issued – on vested RSUs | $ 0 | $ 0 | 0 | 0 | 0 |
Net income | $ 0 | $ 0 | 0 | 4,795 | 4,795 |
Balance (in shares) at Sep. 30, 2020 | 0 | 32,131,165 | |||
Balance at Sep. 30, 2020 | $ 0 | $ 32 | 282,076 | (95,257) | 186,851 |
Balance (in shares) at Jun. 30, 2020 | 0 | 25,982,367 | |||
Balance at Jun. 30, 2020 | $ 0 | $ 26 | 199,941 | (94,124) | 105,843 |
Sale of common stock, net of costs (in shares) | 0 | 5,951,250 | |||
Sale of common stock, net of costs | $ 0 | $ 6 | 80,201 | 0 | 80,207 |
Common stock issued for services (in shares) | 0 | 3,175 | |||
Common stock issued for services | $ 0 | $ 0 | 60 | 0 | 60 |
Stock-based compensation | $ 0 | $ 0 | 1,560 | 0 | 1,560 |
Stock option exercises (in shares) | 0 | 118,000 | |||
Stock option exercises | $ 0 | $ 0 | 244 | 0 | 244 |
Warrant exercises (in shares) | 3,500 | ||||
Warrant exercises | $ 0 | 70 | 0 | 70 | |
Stock issued – on vested RSUs (in shares) | 0 | 72,873 | |||
Stock issued – on vested RSUs | $ 0 | $ 0 | 0 | 0 | 0 |
Net income | $ 0 | $ 0 | 0 | (1,133) | (1,133) |
Balance (in shares) at Sep. 30, 2020 | 0 | 32,131,165 | |||
Balance at Sep. 30, 2020 | $ 0 | $ 32 | $ 282,076 | $ (95,257) | $ 186,851 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - shares | May 14, 2020 | Sep. 30, 2020 |
WAVI Holding AG and Taurus4757 GmbH Warrants [Member] | ||
Cashless warrant exercises (in shares) | 3,871,405 | 3,871,405 |
Cashless warrant exercises (in shares) | 3,879,905 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Cash flows from operating activities | ||
Net income (loss) | $ 4,795,000 | $ (4,640,000) |
Adjustments to reconcile net income to net cash provided by operating activities | ||
Depreciation | 1,454,000 | 373,000 |
Amortization of intangible assets | 2,100,000 | 465,000 |
Non cash lease expense | 455,000 | 361,000 |
Stock-based compensation | 3,818,000 | 2,179,000 |
Loss from equity method investment in SAVSU | 0 | 739,000 |
Gain on acquisition of SAVSU | 0 | (10,108,000) |
Change in fair value of investments | (1,110,000) | 0 |
Change in fair value of contingent consideration | (1,528,000) | 0 |
Change in fair value of warrant liability | (4,467,000) | 14,949,000 |
Stock issued for services | 30,000 | 0 |
Other | 9,000 | 15,000 |
Change in operating assets and liabilities | ||
Accounts receivable, trade, net | (820,000) | (372,000) |
Inventories | (65,000) | (1,730,000) |
Prepaid expenses and other current assets | 68,000 | (272,000) |
Accounts payable | (604,000) | 377,000 |
Other payables | (406,000) | (87,000) |
Accrued compensation and other current liabilities | 689,000 | 65,000 |
Other | (30,000) | (98,000) |
Net cash provided by operating activities | 4,388,000 | 2,216,000 |
Cash flows from investing activities | ||
Investment in iVexSol | 0 | (1,000,000) |
Purchase of property and equipment | (370,000) | (356,000) |
Purchase of assets held for rent, net | (1,791,000) | (453,000) |
Proceeds from sale of equipment | 3,000 | 0 |
Net cash used in investing activities | (2,658,000) | (12,997,000) |
Cash flows from financing activities | ||
Proceeds from PPP Loan | 2,175,000 | 0 |
Payoff of PPP Loan | (2,175,000) | 0 |
Payments of contingent consideration | (483,000) | 0 |
Proceeds from sale of common stock, net of $6.2 million of costs | 100,251,000 | 0 |
Proceeds from exercise of common stock options | 1,028,000 | 841,000 |
Proceeds from exercise of warrants | 40,000 | 553,000 |
Payments of costs related to stock issuance | 0 | (44,000) |
Other | (30,000) | (21,000) |
Net cash provided by financing activities | 100,806,000 | 1,329,000 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 102,536,000 | (9,452,000) |
Cash, cash equivalents and restricted cash - beginning of period | 6,448,000 | 30,657,000 |
Cash, cash equivalents and restricted cash - end of period | 108,984,000 | 21,205,000 |
Non-cash investing and financing activities | ||
Cashless exercise of warrants reclassed from warrant liability to common stock | 33,111,000 | 0 |
Reclassification of warrant liability to equity upon exercise | 110,000 | 1,694,000 |
Purchase of property & equipment not yet paid | 29,000 | 146,000 |
Financing costs paid in a prior period | 130,000 | 0 |
Deferred financing costs not yet paid | 0 | 53,000 |
Purchase of equipment with debt | 270,000 | 0 |
Stock issued as consideration to acquire SAVSU | 0 | 19,932,000 |
Prepayment of Services [Member] | ||
Non-cash investing and financing activities | ||
Stock issued | 30,000 | 0 |
Bonus Consideration [Member] | ||
Non-cash investing and financing activities | ||
Stock issued | 314,000 | 0 |
SciSafe Holdings, Inc [Member] | ||
Cash flows from investing activities | ||
Payments related to the acquisition, net of cash acquired | (500,000) | 0 |
SAVSU [Member] | ||
Cash flows from investing activities | ||
Payments related to the acquisition, net of cash acquired | 0 | 1,251,000 |
Astero [Member] | ||
Cash flows from investing activities | ||
Payments related to the acquisition, net of cash acquired | $ 0 | $ (12,439,000) |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Millions | Jul. 07, 2020 | Sep. 30, 2020 |
Stock issuance costs | $ 6.1 | $ 6.2 |
Note 1 - Organization and Signi
Note 1 - Organization and Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 1. Organization and Significant Accounting Policies Business BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a leading developer, manufacturer and supplier of a portfolio of cell and gene therapy bioproduction products and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, and freezer technology. Our CryoStor® freeze media and HypoThermosol® hypothermic storage are optimized to preserve cells during distribution and storage. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function. Our ThawSTAR® product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products improve the quality of high-value, temperature-sensitive biologic therapies by standardizing the thawing process and reducing the risks of contamination and overheating which are inherent with the use of traditional water baths. Our evo® shipping containers are innovative high-performance cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Basis of Presentation The condensed consolidated financial statements included herein have been prepared by BioLife Solutions, Inc. in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for Quarterly Reports on Form 10 10 X not 10 December 31, 2019. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astero Bio Corporation (“Astero,” and the Astero product line, “ThawSTAR” acquired on April 1, 2019), August 8, 2019), November 12, 2019). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not Financial Statement Reclassification Certain classifications on the Condensed Consolidated Statements of Cash Flows related to non cash lease expense and accrued expenses and other current liabilities for the three nine September 30, 2019 no Significant Accounting Policies There have been no nine September 30, 2020, 10 Liquidity and Capital Resources On September 30, 2020 December 31, 2019, April 1, 2019 2019 second 2020. August 8, 2019, not November 12, 2019, not October 1, 2020, not On July 7, 2020, As of September 30, 2020, third October 1, 2020, Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash and cash equivalents including proceeds from the public offering, will be sufficient to meet our liquidity needs for at least the foreseeable future. However, the Company may 19 may not Risks and Uncertainties COVID- 19 On March 10, 2020, 2, 2019 19” 19 19, not three March 31, 2020, second June 30, 2020, third September 30, 2020, third September 30, 2020 second June 30, 2020. may The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for near term revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no impairment of the remaining long-lived assets as of June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 third September 30, 2020 two not June 30, 2020, September 30, 2020 third September 30, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, may As of March 30, 2020, 50% 2021 50% 2022. Concentrations of credit risk and business risk In the three September 30, 2020, nine September 30, 2020, three September 30, 2019, three nine September 30, 2019, No 10% nine September 30, 2020 2019. three September 30, 2020 2019, 2019 2020, December 31, 2020. September 30, 2020, December 31, 2019, The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended September 30, Nine Months Ended September 30, Revenue by customers’ geographic locations 2020 2019 2020 2019 United States 73 % 76 % 73 % 70 % Canada 11 % 12 % 13 % 17 % Europe, Middle East, Africa (EMEA) 13 % 11 % 12 % 11 % Other 3 % 1 % 2 % 2 % Total revenue 100 % 100 % 100 % 100 % Recent accounting pronouncements In June 2016, No. 2016 13, 326 2016 13 2016 13 December 15, 2022, In August 2018, 2018 13, 820 2018 13 8: December 31, 2020 January 1, 2020 no In August 2018, No. 2018 15, 350 40 2018 15 December 15, 2019, January 1, 2020 no In December 2019, 2019 12, 740 2019 12 740, not 2019 12 December 31, 2021, no 2019 12 |
Note 2 - Fair Value Measurement
Note 2 - Fair Value Measurement | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 2. Fair Value Measurement In accordance with FASB ASC Topic 820, 820” 820 820 three Level 1 Level 2 1 not Level 3 September 30, 2020 December 31, 2019, 3 For the investment in convertible debt, the significant Level 3 September 2019 may The fair value of the Astero contingent consideration liability was initially valued based on unobservable inputs using a Black-Scholes valuation model. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 17.5%, risk-free rates between 2.30% and 2.43% and revenue volatility of 90%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not September 30, 2020, September 30, 2020 December 31, 2019 may The fair value of the CBS contingent consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 26.0%, a risk-free rate of approximately 1.74% and revenue volatility of 70%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not September 30, 2020, September 30, 2020 December 31, 2019 may For the warrant liability, the significant Level 3 one not may There were no nine September 30, 2020 not The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2020 December 31, 2019, three (In thousands) As of September 30, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 93,984 $ — $ — $ 93,984 Restricted cash held in escrow 15,000 — — 15,000 Convertible debt held at fair value — — 2,110 2,110 Total 108,984 — 2,110 111,094 Liabilities: Contingent consideration - business combinations — — 386 386 Warrant liability — — 1,914 1,914 Total $ — $ — $ 2,300 $ 2,300 As of December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 6,448 $ — $ — $ 6,448 Convertible debt held at fair value — — 1,000 1,000 Total 6,448 — 1,000 7,448 Liabilities: Contingent consideration - business combinations — — 1,914 1,914 Warrant liability — — 39,602 39,602 Total $ — $ — $ 41,516 $ 41,516 The fair values of money market funds classified as Level 1 3 no 3 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands) Balance, beginning of period $ 1,000 $ — $ 1,000 $ — Purchases — 1,000 — 1,000 Change in fair value recognized in net income 1,110 — 1,110 — Balance, end of period $ 2,110 $ 1,000 $ 2,110 $ 1,000 The following tables present the changes in fair value of contingent consideration liabilities which are measured using Level 3 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands) Balance, beginning of period $ 388 $ 1,492 $ 1,914 $ — Additions — — — 1,492 Change in fair value recognized in net income (2 ) — (1,528 ) — Payments earned, reclassified to accrued liabilities — — — — Balance, end of period $ 386 $ 1,492 $ 386 $ 1,492 The following tables present the changes in fair value of warrant liabilities which are measured using Level 3 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands) Balance, beginning of period $ 963 $ 44,194 $ 39,602 $ 28,516 Exercised warrants (54 ) (1,295 ) (33,221 ) (1,694 ) Change in fair value recognized in net income 1,005 (1,128 ) (4,467 ) 14,949 Balance, end of period $ 1,914 $ 41,771 $ 1,914 $ 41,771 |
Note 3 - Acquisitions
Note 3 - Acquisitions | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Business Combination Disclosure [Text Block] | 3. Acquisitions Astero Acquisition On April 1, 2019, In connection with the acquisition, the Company paid (i) a base payment in the amount of $12.5 million consisting of an initial cash payment of $8.0 million at the closing of the transactions, subject to adjustment for working capital, net debt and transaction expenses, and a deferred cash payment that was paid into escrow and subsequently paid to Astero of $4.5 million which was payable upon the earlier of Astero meeting certain product development milestones or one 2019, 2020 2021 second 2020 2019 2021, three 2019 2021. Consideration transferred The Astero acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, three not may Total consideration recorded for the acquisition of Astero is as follows (amounts in thousands): Cash consideration $ 12,521 Contingent consideration 1,491 Working capital adjustment (71 ) Total consideration transferred $ 13,941 Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their estimated fair values (amounts in thousands). Such amounts were estimated using the most recent financial statements from Astero as of March 31, 2019. Cash and cash equivalents $ 11 Accounts receivable, net 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 2,840 In-process research and development 650 Goodwill 9,515 Other assets 99 Accounts payable (250 ) Other liabilities (164 ) Fair value of net assets acquired $ 13,941 The fair value of Astero’s identifiable intangible assets and estimated useful lives have been estimated as follows (amounts in thousands except years): Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technology 2,840 5 – 9 In-process research and development 650 9 Total identifiable intangible assets $ 4,120 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three third Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Acquired Goodwill The goodwill of $9.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. All but $1.1 million of the goodwill recorded is not SAVSU Acquisition On August 8, 2019, not August 8, 2019, Consideration transferred The SAVSU acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, 100% not Under the acquisition method of accounting, the assets acquired and liabilities assumed from SAVSU were recorded as of the acquisition date, at their respective fair values, and consolidated with those of BioLife. The fair value of the net tangible assets acquired is estimated to be approximately $4.2 million, the fair value of the intangible assets acquired is estimated to be approximately $12.2 million, and the residual goodwill is estimated to be approximately $19.5 million. The fair value estimates required critical estimates, including, but not may Total consideration paid for the acquisition of SAVSU is as follows (amounts in thousands): Stock consideration for 55.6% equity interest purchased $ 19,932 This stock consideration plus the fair value of our existing equity investment in SAVSU of $15.9 million results in the total purchase price for accounting purposes of $35.8 million. Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their estimated fair values (amounts in thousands). Such amounts were estimated using the most recent financial statements from SAVSU as of August 7, 2019. Cash and cash equivalents $ 1,251 Accounts receivable, net 753 Prepaid expenses and other current assets 19 Property, plant and equipment, net 546 Operating right-of-use asset 233 Assets held for rent, net 2,441 Customer relationships 80 Tradenames 1,320 Developed technology 10,750 Goodwill 21,037 Accounts payable and accrued expenses (807 ) Deferred tax liabilities (1,541 ) Other liabilities (232 ) Fair value of net assets acquired $ 35,850 The fair value of SAVSU’s identifiable intangible assets and estimated useful lives have been estimated as follows (amounts in thousands except years): Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technology 10,750 7 – 8 Total identifiable intangible assets $ 12,150 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Acquired Goodwill The goodwill of $21.0 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. None Custom Biogenic Systems Acquisition On November 10, 2019, November 12, 2019. In connection with the CBS Acquisition, we paid to CBS (i) a base payment in the amount of $15.0 million, consisting of a cash payment of $11.0 million paid at the closing of the CBS Acquisition, less a cash holdback escrow of $550,000 to satisfy certain indemnification claims, and an aggregate number of shares of our common stock, with an aggregate fair value equal to $4.0 million, less a holdback escrow of shares of Common Stock with an aggregate value equal to $3.0 million to satisfy potential payments related to any product liability claims outstanding as of March 13, 2019, 2020, 2021, 2022, 2023 2024 not The CBS Acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, not may Total consideration transferred (in thousands): Cash consideration $ 11,000 Stock consideration 4,000 Contingent consideration 856 Total consideration transferred $ 15,856 Fair Value of Net Assets Acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Such amounts were estimated using the most recent financial statements from CBS as of November 11, 2019. Accounts receivable, net $ 1,044 Inventory 3,232 Prepaid expenses and other current assets 29 Property, plant and equipment, net 3,615 Customer relationships 560 Tradenames 800 Developed technology 5,430 Goodwill 2,954 Accounts payable (1,197 ) Other liabilities (611 ) Fair value of net assets acquired $ 15,856 The fair value of CBS’s identifiable intangible assets and weighted average useful lives have been estimated as follows (amounts in thousands except years): Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 560 6 Tradenames 800 6 Developed technology 5,430 9 Total identifiable intangible assets $ 6,790 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Acquired Goodwill The goodwill of $3.0 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. All of the goodwill recorded is expected to be deductible for income tax purposes. |
Note 4 - Inventory
Note 4 - Inventory | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 4. Inventory Inventory consists of the following at September 30, 2020 December 31, 2019: (In thousands) September 30, 2020 December 31, 2019 Raw materials $ 2,731 $ 2,979 Work in progress 2,252 1,896 Finished goods 6,054 6,097 Total $ 11,037 $ 10,972 |
Note 5 - Assets Held for Rent
Note 5 - Assets Held for Rent | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Assets Held For Rent [Text Block] | 5. Assets held for rent Assets held for rent consist of the following at September 30, 2020 December 31, 2019: (In thousands) September 30, 2020 December 31, 2019 Shippers placed in service $ 4,666 $ 3,073 Accumulated deprecation (755 ) (174 ) Net 3,911 2,899 Shippers and related components in production 1,220 1,023 Total $ 5,131 $ 3,922 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $186,000 and $581,000 in depreciation expense related to assets held for rent during the three nine September 30, 2020. three nine September 30, 2019. |
Note 6 - Goodwill and Intangibl
Note 6 - Goodwill and Intangible Assets | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 6. Goodwill and Intangible Assets Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination and determined to have an indefinite useful life is not 350. nine September 30, 2020: (In thousands) Balance as of December 31, 2019 $ 33,637 Correction of an error related to CBS goodwill (131 ) Balance as of September 30, 2020 $ 33,506 We adjusted goodwill from the CBS Acquisition related to an immaterial error of $131,000 in payables that were paid during closing and incorrectly recorded as liabilities in our purchase price accounting as of December 31, 2019. Intangible Assets Intangible assets, net consisted of the following at September 30, 2020: (In thousands, except weighted average useful life) September 30, 2020 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 800 $ (161 ) $ 639 4.5 Tradenames 2,590 (372 ) 2,218 6.9 Technology – acquired (1) 19,670 (2,646 ) 17,024 7.3 Total intangible assets $ 23,060 $ (3,179 ) $ 19,881 7.2 ( 1 April 1, 2020, Intangible assets, net consisted of the following at December 31, 2019: (In thousands, except weighted average useful life) December 31, 2019 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 800 $ (51 ) $ 749 5.6 Tradenames 2,590 (123 ) 2,467 8.1 Technology – acquired 19,020 (904 ) 18,116 8.4 In-process R&D (2) 650 — 650 9.0 Total intangible assets $ 23,060 $ (1,078 ) $ 21,982 8.3 ( 2 not April 1, 2020, 1 Amortization expense for finite-lived intangible assets was $706,000 and $2.1 million for the three nine September 30, 2020, three nine September 30, 2019. second 2020, September 30, 2020, (In thousands) For the Years Ended December 31, Estimated Amortization Expense 2020 (3 months remaining) $ 705 2021 2,825 2022 2,825 2023 2,795 2024 2,770 Thereafter 7,961 Total $ 19,881 |
Note 7 - Share-based Compensati
Note 7 - Share-based Compensation | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 7. Share-based Compensation Service Vesting-Based Stock Options The following is a summary of service vesting-based stock option activity for the nine September 30, 2020 September 30, 2020: Nine Month Period Ended September 30, 2020 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 1,570,455 $ 1.96 Granted — $ — Exercised (511,680 ) $ 1.95 Forfeited — $ — Expired — $ — Outstanding service vesting-based at September 30, 2020 1,058,775 $ 1.96 Service vesting-based options exercisable at September 30, 2020 1,039,399 $ 1.94 We recognized stock compensation expense related to service vesting-based options of $15,000 and $65,000 during the three September 30, 2020 2019, nine September 30, 2020 September 30, 2019, September 30, 2020, September 30, 2020. three September 30, 2020 2019 nine September 30, 2020 2019 nine September 30, 2020 2019. September 30, 2020 September 30, 2020 Performance-based Stock Options The following is a summary of performance-based stock option activity for the nine September 30, 2020, September 30, 2020: Nine Month Period Ended September 30, 2020 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 737,497 $ 1.64 Granted — $ — Exercised (17,113 ) $ 1.64 Outstanding performance-based at September 30, 2020 720,384 $ 1.64 Performance-based options exercisable at September 30, 2020 720,384 $ 1.64 All compensation cost of performance-based stock options outstanding was recognized as of December 31, 2018. September 30, 2020, September 30, 2020. three nine September 30, 2020 none three nine September 30, 2019 September 30, 2020 There were no three nine September 30, 2020 2019. Restricted Stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the nine September 30, 2020, September 30, 2020: Nine Month Period Ended September 30, 2020 Service vesting-based restricted stock Number of Grant-Date Outstanding at beginning of year 429,399 $ 13.25 Granted 448,267 $ 15.78 Granted in lieu of cash 34,154 $ 9.18 Vested (161,263 ) $ 11.12 Forfeited (24,861 ) $ 14.80 Outstanding at September 30, 2020 725,696 $ 15.04 The aggregate fair value of the service vesting-based awards granted during the three September 30, 2020 2019 nine September 30, 2020 2019 three September 30, 2020 2019 nine September 30, 2020 2019 On March 25, 2020, 2019 September 25, 2020 December 31, 2019. We recognized stock compensation expense of $754,000 and $303,000 related to service vesting-based awards for the three September 30, 2020 2019, nine September 30, 2020 2019, September 30, 2020, Performance-based restricted stock On March 25, 2020, 2020 December 31, 2020. The following is a summary of performance-based restricted stock activity for the nine September 30, 2020, September 30, 2020: Nine Month Period Ended September 30, 2020 Performance-based restricted stock Number of Grant-Date Outstanding at beginning of year — $ — Expected to vest 82,805 $ 9.18 Vested — $ — Forfeited — $ — Outstanding at September 30, 2020 82,805 $ 9.18 We recognized stock compensation expense of $191,000 and $569,000 related to performance-based restricted stock awards for the three nine September 30, 2020, September 30, 2020, Market-based restricted stock On February 25, 2019, April 1, 2019 January 1, 2019 December 31, 2020 20 2 0% December 31, 2020. On March 25, 2020, January 1, 2020 December 31, 2021 20 0% 2 December 31, 2021. We recognized stock compensation expense of $600,000 and $461,000 related to market-based restricted stock awards for the three September 30, 2020 2019, nine September 30, 2020 2019, September 30, 2020, Total Stock Compensation Expense We recorded total stock compensation expense for the three nine September 30, 2020 2019, Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2020 2019 2020 2019 Research and development costs $ 291 $ 165 $ 687 $ 400 Sales and marketing costs 256 182 581 507 General and administrative costs 868 429 2,144 1,145 Cost of product sales 145 53 406 127 Total $ 1,560 $ 829 $ 3,818 $ 2,179 |
Note 8 - Warrants
Note 8 - Warrants | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Warrants [Text Block] | 8. Warrants In March 2014, March 2021. In May 2016, May 2021. On May 14, 2020, Taurus4757 Additionally, during the three nine September 30, 2020, March 2021. The following table summarizes warrant activity for the nine September 30, 2020: Shares Wtd. Avg. Exercise Price Outstanding at December 31, 2019 3,959,005 $ 4.33 Exercised (3,879,905 ) 4.33 Outstanding at September 30, 2020 79,100 $ 4.75 |
Note 9 - Income Taxes
Note 9 - Income Taxes | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 9. Income Taxes The Company accounts for income taxes under ASC Topic 740 We have recorded a full valuation allowance against our deferred tax assets. If we have multiple quarters of positive net income, we will assess our valuation allowance. Based on all available evidence, we determined that we have not September 30, 2020. may On March 27, 2020, no 2020 As of March 30, 2020, 50% 2021 50% 2022. |
Note 10 - Net Income (Loss) Per
Note 10 - Net Income (Loss) Per Common Share | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 10. Net Income (Loss) per Common Share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two three September 30, 2020, 63,000 nine September 30, 2019, 146,000 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands, except per share and share data) Basic earnings (loss) per common share Numerator: Net income (loss) $ (1,133 ) $ 10,269 $ 4,795 $ (4,640 ) Amount attributable to unvested restricted shares — (207 ) (138 ) — Amount attributable to warrants outstanding — (1,682 ) (335 ) — Net income (loss) allocated to common shareholders (1,133 ) 8,380 4,322 (4,640 ) Denominator: Weighted-average common shares issued and outstanding 31,639,420 19,735,364 25,418,375 19,071,722 Basic earnings (loss) per common share (0.04 ) 0.42 0.17 (0.24 ) Diluted earnings (loss) per common share Numerator: Net income (loss) (1,133 ) 10,269 4,795 (4,640 ) Amount attributable to non-participating warrants — (279 ) (49 ) — Less: gain related to change in fair value of warrants — (1,128 ) (4,467 ) — Diluted net income (loss) allocated to common shareholders (1,133 ) 8,862 279 (4,640 ) Denominator: Weighted-average common shares issued and outstanding 31,639,420 19,735,364 25,418,375 19,071,722 Dilutive potential common shares: Stock options — 2,420,884 1,754,051 — Restricted stock awards — 140,501 285,975 — Warrants — 3,046,363 1,954,137 — Diluted weighted-average shares issued and outstanding 31,639,420 25,343,112 29,412,538 19,071,722 Diluted earnings (loss) per common share (0.04 ) 0.35 0.01 (0.24 ) |
Note 11 - Commitments and Conti
Note 11 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 11. Commitments & Contingencies Employment agreements We have employment agreements with our Chief Executive Officer, Chief Financial and Operating Officer, Chief Science Officer, Chief Quality Officer, Chief Marketing Officer, Vice President - Freezer Technologies, Vice President of Sales - Thaw Technologies, Vice President of Product Development - Thaw Technologies, and Vice President - Global Sales. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not September 30, 2020. |
Note 12 - Revenue
Note 12 - Revenue | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 12. Revenue We currently operate as one We generate revenue from the sale of bioproduction products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. Under ASC 606, The Company also generates revenue from the leasing of our evo cold chain systems, which are typically cloud-connected shippers with enabling cold chain cloud applications, to customers pursuant to rental arrangements entered into with the customer. Revenue from the rental of cold chain systems is not 606 842, The following table represents revenues by product line: Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2020 2019 2020 2019 Biopreservation media $ 7,414 $ 6,069 $ 22,753 $ 18,165 Automated thawing 277 324 1,047 699 evo shippers 494 211 1,372 211 Freezers and accessories 3,094 — 8,189 — Total $ 11,279 $ 6,604 $ 33,361 $ 19,075 |
Note 13 - Leases
Note 13 - Leases | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Lessee, Leases [Text Block] | 13. Leases We lease approximately 32,106 square feet in our Bothell, Washington headquarters. The term of our lease continues until July 31, 2021 two five first August 1, 2021, second first September 30, 2020, August October We lease approximately 1,250 square feet in our Menlo Park, California location. The lease is on a month-to-month term. In accordance with the lease agreement, the monthly base rent is approximately $5,000 at September 30, 2020. We lease approximately 9,932 square feet in our Albuquerque, New Mexico location. The term of our lease continues until December 31, 2021 two three first December 1, 2021, second December 1, 2024. September 30, 2020, We lease approximately 106,998 square feet in our Detroit, Michigan location. The term of our lease continues until November 30, 2020 one sixty November 12, 2020. not 842, not 12 two not September 30, 2020, Operating leases recorded on our condensed consolidated balance sheet are primarily related to our Bothell, Washington headquarters space lease and our Albuquerque, New Mexico, SAVSU, space lease. We have not not not one Our financing lease is related to research equipment. We used a weighted average discount rate of 6.5%, our market collateralized borrowing rate, and 8.1%, the weighted average implied interest on our leases, to determine our operating and financing lease liabilities, respectively. The weighted average remaining term of our operating and financing leases are 1 year and 0.4 years, respectively. We initially recognized $1.3 million in operating lease right of use assets and initially recognized $1.8 million in operating lease liabilities. Through the SAVSU acquisition we acquired $233,000 in operating lease right of use assets and acquired $232,000 in operating lease liabilities. The operating lease costs recognized in the three September 30, 2020 not nine September 30, 2020 not three nine September 30, 2020 three nine September 30, 2019, Maturities of our operating lease liabilities as of September 30, 2020 (In thousands) Operating Leases Financing Leases 2020 220 4 2021 559 2 Total lease payments 779 6 Less: interest (24 ) (1 ) Total present value of lease liabilities $ 755 $ 5 |
Note 14 - Condensed Consolidate
Note 14 - Condensed Consolidated Balance Sheet Detail | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 14. Condensed Consolidated Balance Sheet Detail Property and Equipment (In thousands) September 30, 2020 December 31, 2019 Property and equipment Leasehold improvements $ 2,145 $ 2,112 Furniture and computer equipment 827 794 Manufacturing and other equipment 5,707 5,187 Subtotal 8,679 8,093 Less: Accumulated depreciation (3,379 ) (2,521 ) Net property and equipment $ 5,300 $ 5,572 Depreciation expense for property and equipment was $296,000 and $114,000 for the three September 30, 2020 2019, nine September 30, 2020 2019, Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: (In thousands) September 30, 2020 December 31, 2019 Accrued expenses and other current liabilities $ 275 $ 302 Other payables 208 1,018 Accrued compensation 2,538 1,554 Deferred revenue 334 324 Other 9 171 Total accrued expenses and other current liabilities $ 3,364 $ 3,369 |
Note 15 - Employee Benefit Plan
Note 15 - Employee Benefit Plan | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Defined Contribution Plan [Text Block] | 15. Employee Benefit Plan The Company sponsors a 401 may three September 30, 2020 2019, nine September 30, 2020 2019, |
Note 16 - Subsequent Event
Note 16 - Subsequent Event | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 16. Subsequent Event SciSafe Acquisition On October 1, 2020, October 1, 2020. January 2021. may 2021, 2022, 2023 2024 We incurred $179,000 of related acquisition costs for the three September 30, 2020, October 1, 2020. Due to the limited time since the acquisition date and the effort required to assess the fair value of assets acquired and liabilities assumed, the initial accounting for the business combination is incomplete at the time of this filing. As a result, the Company is unable to provide the amounts recognized for the major classes of assets acquired and liabilities assumed, acquisition contingencies and goodwill. Also, the Company is unable to provide pro forma revenues and earnings of the combined entity. This information is expected to be included in the Company's Annual Report on Form 10 December 31, 2020. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The condensed consolidated financial statements included herein have been prepared by BioLife Solutions, Inc. in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for Quarterly Reports on Form 10 10 X not 10 December 31, 2019. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astero Bio Corporation (“Astero,” and the Astero product line, “ThawSTAR” acquired on April 1, 2019), August 8, 2019), November 12, 2019). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not Financial Statement Reclassification Certain classifications on the Condensed Consolidated Statements of Cash Flows related to non cash lease expense and accrued expenses and other current liabilities for the three nine September 30, 2019 no |
Liquidity and Capital Resources, Policy [Policy Text Block] | Liquidity and Capital Resources On September 30, 2020 December 31, 2019, April 1, 2019 2019 second 2020. August 8, 2019, not November 12, 2019, not October 1, 2020, not On July 7, 2020, As of September 30, 2020, third October 1, 2020, Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash and cash equivalents including proceeds from the public offering, will be sufficient to meet our liquidity needs for at least the foreseeable future. However, the Company may 19 may not |
Risk and Uncertainties, Policy [Policy Text Block] | Risks and Uncertainties COVID- 19 On March 10, 2020, 2, 2019 19” 19 19, not three March 31, 2020, second June 30, 2020, third September 30, 2020, third September 30, 2020 second June 30, 2020. may The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for near term revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no impairment of the remaining long-lived assets as of June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 third September 30, 2020 two not June 30, 2020, September 30, 2020 third September 30, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, may As of March 30, 2020, 50% 2021 50% 2022. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of credit risk and business risk In the three September 30, 2020, nine September 30, 2020, three September 30, 2019, three nine September 30, 2019, No 10% nine September 30, 2020 2019. three September 30, 2020 2019, 2019 2020, December 31, 2020. September 30, 2020, December 31, 2019, The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended September 30, Nine Months Ended September 30, Revenue by customers’ geographic locations 2020 2019 2020 2019 United States 73 % 76 % 73 % 70 % Canada 11 % 12 % 13 % 17 % Europe, Middle East, Africa (EMEA) 13 % 11 % 12 % 11 % Other 3 % 1 % 2 % 2 % Total revenue 100 % 100 % 100 % 100 % |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent accounting pronouncements In June 2016, No. 2016 13, 326 2016 13 2016 13 December 15, 2022, In August 2018, 2018 13, 820 2018 13 8: December 31, 2020 January 1, 2020 no In August 2018, No. 2018 15, 350 40 2018 15 December 15, 2019, January 1, 2020 no In December 2019, 2019 12, 740 2019 12 740, not 2019 12 December 31, 2021, no 2019 12 |
Note 1 - Organization and Sig_2
Note 1 - Organization and Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Revenue from External Customers by Products and Services [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, Revenue by customers’ geographic locations 2020 2019 2020 2019 United States 73 % 76 % 73 % 70 % Canada 11 % 12 % 13 % 17 % Europe, Middle East, Africa (EMEA) 13 % 11 % 12 % 11 % Other 3 % 1 % 2 % 2 % Total revenue 100 % 100 % 100 % 100 % |
Note 2 - Fair Value Measureme_2
Note 2 - Fair Value Measurement (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | As of September 30, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 93,984 $ — $ — $ 93,984 Restricted cash held in escrow 15,000 — — 15,000 Convertible debt held at fair value — — 2,110 2,110 Total 108,984 — 2,110 111,094 Liabilities: Contingent consideration - business combinations — — 386 386 Warrant liability — — 1,914 1,914 Total $ — $ — $ 2,300 $ 2,300 As of December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 6,448 $ — $ — $ 6,448 Convertible debt held at fair value — — 1,000 1,000 Total 6,448 — 1,000 7,448 Liabilities: Contingent consideration - business combinations — — 1,914 1,914 Warrant liability — — 39,602 39,602 Total $ — $ — $ 41,516 $ 41,516 |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands) Balance, beginning of period $ 1,000 $ — $ 1,000 $ — Purchases — 1,000 — 1,000 Change in fair value recognized in net income 1,110 — 1,110 — Balance, end of period $ 2,110 $ 1,000 $ 2,110 $ 1,000 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands) Balance, beginning of period $ 388 $ 1,492 $ 1,914 $ — Additions — — — 1,492 Change in fair value recognized in net income (2 ) — (1,528 ) — Payments earned, reclassified to accrued liabilities — — — — Balance, end of period $ 386 $ 1,492 $ 386 $ 1,492 |
Warrant Liabilities [Member] | |
Notes Tables | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands) Balance, beginning of period $ 963 $ 44,194 $ 39,602 $ 28,516 Exercised warrants (54 ) (1,295 ) (33,221 ) (1,694 ) Change in fair value recognized in net income 1,005 (1,128 ) (4,467 ) 14,949 Balance, end of period $ 1,914 $ 41,771 $ 1,914 $ 41,771 |
Note 3 - Acquisitions (Tables)
Note 3 - Acquisitions (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | Cash consideration $ 12,521 Contingent consideration 1,491 Working capital adjustment (71 ) Total consideration transferred $ 13,941 Stock consideration for 55.6% equity interest purchased $ 19,932 Cash consideration $ 11,000 Stock consideration 4,000 Contingent consideration 856 Total consideration transferred $ 15,856 |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | Cash and cash equivalents $ 11 Accounts receivable, net 154 Inventory 456 Customer relationships 160 Tradenames 470 Developed technology 2,840 In-process research and development 650 Goodwill 9,515 Other assets 99 Accounts payable (250 ) Other liabilities (164 ) Fair value of net assets acquired $ 13,941 Cash and cash equivalents $ 1,251 Accounts receivable, net 753 Prepaid expenses and other current assets 19 Property, plant and equipment, net 546 Operating right-of-use asset 233 Assets held for rent, net 2,441 Customer relationships 80 Tradenames 1,320 Developed technology 10,750 Goodwill 21,037 Accounts payable and accrued expenses (807 ) Deferred tax liabilities (1,541 ) Other liabilities (232 ) Fair value of net assets acquired $ 35,850 Accounts receivable, net $ 1,044 Inventory 3,232 Prepaid expenses and other current assets 29 Property, plant and equipment, net 3,615 Customer relationships 560 Tradenames 800 Developed technology 5,430 Goodwill 2,954 Accounts payable (1,197 ) Other liabilities (611 ) Fair value of net assets acquired $ 15,856 |
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] | Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 160 4 Tradenames 470 9 Developed technology 2,840 5 – 9 In-process research and development 650 9 Total identifiable intangible assets $ 4,120 Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 80 6 Tradenames 1,320 9 Developed technology 10,750 7 – 8 Total identifiable intangible assets $ 12,150 Estimated Fair Value Estimated Useful Life (Years) Customer relationships $ 560 6 Tradenames 800 6 Developed technology 5,430 9 Total identifiable intangible assets $ 6,790 |
Note 4 - Inventory (Tables)
Note 4 - Inventory (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | (In thousands) September 30, 2020 December 31, 2019 Raw materials $ 2,731 $ 2,979 Work in progress 2,252 1,896 Finished goods 6,054 6,097 Total $ 11,037 $ 10,972 |
Note 5 - Assets Held for Rent (
Note 5 - Assets Held for Rent (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Scheduleof Assets Held for Rent [Table Text Block] | (In thousands) September 30, 2020 December 31, 2019 Shippers placed in service $ 4,666 $ 3,073 Accumulated deprecation (755 ) (174 ) Net 3,911 2,899 Shippers and related components in production 1,220 1,023 Total $ 5,131 $ 3,922 |
Note 6 - Goodwill and Intangi_2
Note 6 - Goodwill and Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Goodwill [Table Text Block] | (In thousands) Balance as of December 31, 2019 $ 33,637 Correction of an error related to CBS goodwill (131 ) Balance as of September 30, 2020 $ 33,506 |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | (In thousands, except weighted average useful life) September 30, 2020 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 800 $ (161 ) $ 639 4.5 Tradenames 2,590 (372 ) 2,218 6.9 Technology – acquired (1) 19,670 (2,646 ) 17,024 7.3 Total intangible assets $ 23,060 $ (3,179 ) $ 19,881 7.2 (In thousands, except weighted average useful life) December 31, 2019 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 800 $ (51 ) $ 749 5.6 Tradenames 2,590 (123 ) 2,467 8.1 Technology – acquired 19,020 (904 ) 18,116 8.4 In-process R&D (2) 650 — 650 9.0 Total intangible assets $ 23,060 $ (1,078 ) $ 21,982 8.3 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | (In thousands) For the Years Ended December 31, Estimated Amortization Expense 2020 (3 months remaining) $ 705 2021 2,825 2022 2,825 2023 2,795 2024 2,770 Thereafter 7,961 Total $ 19,881 |
Note 7 - Share-based Compensa_2
Note 7 - Share-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Nine Month Period Ended September 30, 2020 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 1,570,455 $ 1.96 Granted — $ — Exercised (511,680 ) $ 1.95 Forfeited — $ — Expired — $ — Outstanding service vesting-based at September 30, 2020 1,058,775 $ 1.96 Service vesting-based options exercisable at September 30, 2020 1,039,399 $ 1.94 Nine Month Period Ended September 30, 2020 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 737,497 $ 1.64 Granted — $ — Exercised (17,113 ) $ 1.64 Outstanding performance-based at September 30, 2020 720,384 $ 1.64 Performance-based options exercisable at September 30, 2020 720,384 $ 1.64 |
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] | Nine Month Period Ended September 30, 2020 Service vesting-based restricted stock Number of Grant-Date Outstanding at beginning of year 429,399 $ 13.25 Granted 448,267 $ 15.78 Granted in lieu of cash 34,154 $ 9.18 Vested (161,263 ) $ 11.12 Forfeited (24,861 ) $ 14.80 Outstanding at September 30, 2020 725,696 $ 15.04 Nine Month Period Ended September 30, 2020 Performance-based restricted stock Number of Grant-Date Outstanding at beginning of year — $ — Expected to vest 82,805 $ 9.18 Vested — $ — Forfeited — $ — Outstanding at September 30, 2020 82,805 $ 9.18 |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2020 2019 2020 2019 Research and development costs $ 291 $ 165 $ 687 $ 400 Sales and marketing costs 256 182 581 507 General and administrative costs 868 429 2,144 1,145 Cost of product sales 145 53 406 127 Total $ 1,560 $ 829 $ 3,818 $ 2,179 |
Note 8 - Warrants (Tables)
Note 8 - Warrants (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Shares Wtd. Avg. Exercise Price Outstanding at December 31, 2019 3,959,005 $ 4.33 Exercised (3,879,905 ) 4.33 Outstanding at September 30, 2020 79,100 $ 4.75 |
Note 10 - Net Income (Loss) P_2
Note 10 - Net Income (Loss) Per Common Share (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 (In thousands, except per share and share data) Basic earnings (loss) per common share Numerator: Net income (loss) $ (1,133 ) $ 10,269 $ 4,795 $ (4,640 ) Amount attributable to unvested restricted shares — (207 ) (138 ) — Amount attributable to warrants outstanding — (1,682 ) (335 ) — Net income (loss) allocated to common shareholders (1,133 ) 8,380 4,322 (4,640 ) Denominator: Weighted-average common shares issued and outstanding 31,639,420 19,735,364 25,418,375 19,071,722 Basic earnings (loss) per common share (0.04 ) 0.42 0.17 (0.24 ) Diluted earnings (loss) per common share Numerator: Net income (loss) (1,133 ) 10,269 4,795 (4,640 ) Amount attributable to non-participating warrants — (279 ) (49 ) — Less: gain related to change in fair value of warrants — (1,128 ) (4,467 ) — Diluted net income (loss) allocated to common shareholders (1,133 ) 8,862 279 (4,640 ) Denominator: Weighted-average common shares issued and outstanding 31,639,420 19,735,364 25,418,375 19,071,722 Dilutive potential common shares: Stock options — 2,420,884 1,754,051 — Restricted stock awards — 140,501 285,975 — Warrants — 3,046,363 1,954,137 — Diluted weighted-average shares issued and outstanding 31,639,420 25,343,112 29,412,538 19,071,722 Diluted earnings (loss) per common share (0.04 ) 0.35 0.01 (0.24 ) |
Note 12 - Revenue (Tables)
Note 12 - Revenue (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Revenues By Product Line [Table Text Block] | Three Month Period Ended Nine Month Period Ended September 30, September 30, (In thousands) 2020 2019 2020 2019 Biopreservation media $ 7,414 $ 6,069 $ 22,753 $ 18,165 Automated thawing 277 324 1,047 699 evo shippers 494 211 1,372 211 Freezers and accessories 3,094 — 8,189 — Total $ 11,279 $ 6,604 $ 33,361 $ 19,075 |
Note 13 - Leases (Tables)
Note 13 - Leases (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | (In thousands) Operating Leases Financing Leases 2020 220 4 2021 559 2 Total lease payments 779 6 Less: interest (24 ) (1 ) Total present value of lease liabilities $ 755 $ 5 |
Note 14 - Condensed Consolida_2
Note 14 - Condensed Consolidated Balance Sheet Detail (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | (In thousands) September 30, 2020 December 31, 2019 Property and equipment Leasehold improvements $ 2,145 $ 2,112 Furniture and computer equipment 827 794 Manufacturing and other equipment 5,707 5,187 Subtotal 8,679 8,093 Less: Accumulated depreciation (3,379 ) (2,521 ) Net property and equipment $ 5,300 $ 5,572 |
Schedule of Accrued Liabilities [Table Text Block] | (In thousands) September 30, 2020 December 31, 2019 Accrued expenses and other current liabilities $ 275 $ 302 Other payables 208 1,018 Accrued compensation 2,538 1,554 Deferred revenue 334 324 Other 9 171 Total accrued expenses and other current liabilities $ 3,364 $ 3,369 |
Note 1 - Organization and Sig_3
Note 1 - Organization and Significant Accounting Policies (Details Textual) | Oct. 01, 2020USD ($)shares | Jul. 07, 2020USD ($)$ / sharesshares | Nov. 12, 2019USD ($) | Aug. 08, 2019shares | Apr. 01, 2019USD ($) | Sep. 30, 2020USD ($) | Jun. 30, 2020USD ($) | Sep. 30, 2019 | Jun. 30, 2020USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Dec. 31, 2019USD ($) |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance | $ 109,000,000 | $ 109,000,000 | $ 6,400,000 | |||||||||
Payment for Contingent Consideration Liability, Financing Activities | 483,000 | $ 0 | ||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 0 | $ 19,932,000 | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 5,951,250 | |||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 14.50 | |||||||||||
Payments of Stock Issuance Costs | $ 6,100,000 | 6,200,000 | ||||||||||
Proceeds from Issuance of Common Stock, Net | $ 80,200,000 | |||||||||||
Impairment of Intangible Assets (Excluding Goodwill), Total | $ 0 | |||||||||||
Business Combination, Contingent Consideration, Liability, Total | $ 386,000 | $ 388,000 | $ 388,000 | $ 386,000 | ||||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | ||||||||||||
Concentration Risk, Percentage | 11.00% | 33.00% | 12.00% | 17.00% | ||||||||
Number of Major Customers | 1 | 1 | 1 | |||||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | ||||||||||||
Concentration Risk, Percentage | 32.00% | 25.00% | ||||||||||
Number of Major Customers | 2 | 2 | ||||||||||
Product Concentration Risk [Member] | Revenue Benchmark [Member] | CryoStor Products [Member] | ||||||||||||
Concentration Risk, Percentage | 62.00% | 81.00% | ||||||||||
Over-Allotment Option [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 776,250 | |||||||||||
Astero [Member] | ||||||||||||
Payments to Acquire Businesses, Gross | $ 12,521,000 | |||||||||||
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High | 8,500,000 | |||||||||||
Payment for Contingent Consideration Liability, Financing Activities | $ 483,000 | |||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares | 1,100,000 | |||||||||||
Payments to Acquire Businesses, Initial Cash Payment | 8,000,000 | |||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 8,500,000 | |||||||||||
Business Combination, Contingent Consideration, Liability, Total | $ 1,500,000 | $ 80,000 | $ 80,000 | $ 1,100,000 | ||||||||
CBS Acquisition [Member] | ||||||||||||
Payments to Acquire Businesses, Gross | $ 11,000,000 | |||||||||||
Payments to Acquire Businesses, Initial Cash Payment | 11,000,000 | |||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 4,000,000 | |||||||||||
Business Combination, Contingent Consideration, Liability, Total | $ 306,000 | $ 306,000 | $ 856,000 | |||||||||
CBS Acquisition [Member] | Earning Payments Payable in Each Calendar Year 2020, 2021, 2022, 2023, and 2024 [Member] | ||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 15,000,000 | |||||||||||
SciSafe Holdings, Inc [Member] | Subsequent Event [Member] | ||||||||||||
Payments to Acquire Businesses, Gross | $ 15,000,000 | |||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares | 611,383 | |||||||||||
Business Combination Contingent Consideration Stock Issuable High Range | $ 626,000 |
Note 1 - Organization and Sig_4
Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - Revenue Benchmark [Member] - Geographic Concentration Risk [Member] | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Revenue by customers’ geographic locations, percentage | 100.00% | 100.00% | 100.00% | 100.00% |
UNITED STATES | ||||
Revenue by customers’ geographic locations, percentage | 73.00% | 76.00% | 73.00% | 70.00% |
CANADA | ||||
Revenue by customers’ geographic locations, percentage | 11.00% | 12.00% | 13.00% | 17.00% |
EMEA [Member] | ||||
Revenue by customers’ geographic locations, percentage | 13.00% | 11.00% | 12.00% | 11.00% |
Geographic, Other [Member] | ||||
Revenue by customers’ geographic locations, percentage | 3.00% | 1.00% | 2.00% | 2.00% |
Note 2 - Fair Value Measureme_3
Note 2 - Fair Value Measurement (Details Textual) | 9 Months Ended | ||||
Sep. 30, 2020USD ($) | Jun. 30, 2020USD ($) | Dec. 31, 2019USD ($) | Nov. 10, 2019 | Apr. 01, 2019USD ($) | |
Business Combination, Contingent Consideration, Liability, Total | $ 386,000 | $ 388,000 | |||
Astero [Member] | |||||
Business Combination, Contingent Consideration, Liability, Total | 80,000 | $ 1,100,000 | $ 1,500,000 | ||
CBS Acquisition [Member] | |||||
Business Combination, Contingent Consideration, Liability, Total | $ 306,000 | $ 856,000 | |||
Measurement Input, Risk Free Interest Rate [Member] | CBS Acquisition [Member] | |||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.25 | 1.74 | |||
Measurement Input, Discount Rate [Member] | Astero [Member] | |||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 12.5 | 17.5 | |||
Measurement Input, Discount Rate [Member] | CBS Acquisition [Member] | |||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 23 | 26 | |||
Measurement Input, Price Volatility [Member] | Astero [Member] | |||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 64 | 90 | |||
Measurement Input, Price Volatility [Member] | CBS Acquisition [Member] | |||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 63 | 70 | |||
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Astero [Member] | |||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.08 | 2.30 | |||
Minimum [Member] | Measurement Input, Price Volatility [Member] | |||||
Warrants and Rights Outstanding, Measurement Input | 0.640 | ||||
Maximum [Member] | |||||
Warrants and Rights Outstanding, Term (Year) | 1 year | ||||
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Astero [Member] | |||||
Business Combination, Contingent Consideration, Liability, Measurement Input | 0.12 | 2.43 | |||
Maximum [Member] | Measurement Input, Price Volatility [Member] | |||||
Warrants and Rights Outstanding, Measurement Input | 0.846 | ||||
Convertible Debt Securities [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||
Debt Securities, Trading, Measurement Input | 0.080 | ||||
Convertible Debt Securities [Member] | Minimum [Member] | |||||
Debt Securities, Term (Year) | 1 year | ||||
Convertible Debt Securities [Member] | Minimum [Member] | Measurement Input, Prepayment Rate [Member] | |||||
Debt Securities, Trading, Measurement Input | 5 | ||||
Convertible Debt Securities [Member] | Maximum [Member] | |||||
Debt Securities, Term (Year) | 2 years | ||||
Convertible Debt Securities [Member] | Maximum [Member] | Measurement Input, Prepayment Rate [Member] | |||||
Debt Securities, Trading, Measurement Input | 50 |
Note 2 - Fair Value Measureme_4
Note 2 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Assets | $ 111,094 | $ 7,448 |
Liabilities | 2,300 | 41,516 |
Contingent Consideration Liabilities [Member] | ||
Liabilities | 386 | |
Warrant Liabilities [Member] | ||
Liabilities | 1,914 | 39,602 |
Money Market Funds [Member] | ||
Assets | 93,984 | 6,448 |
Restricted Cash Held in Escrow [Member] | ||
Assets | 15,000 | |
Convertible Debt Securities [Member] | ||
Assets | 2,110 | 1,000 |
Contingent Consideration Liabilities [Member] | ||
Liabilities | 1,914 | |
Fair Value, Inputs, Level 1 [Member] | ||
Assets | 108,984 | 6,448 |
Liabilities | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member] | ||
Liabilities | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | ||
Assets | 93,984 | 6,448 |
Fair Value, Inputs, Level 1 [Member] | Restricted Cash Held in Escrow [Member] | ||
Assets | 15,000 | |
Fair Value, Inputs, Level 1 [Member] | Convertible Debt Securities [Member] | ||
Assets | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 2 [Member] | ||
Assets | 0 | 0 |
Liabilities | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member] | ||
Liabilities | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member] | ||
Assets | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Restricted Cash Held in Escrow [Member] | ||
Assets | 0 | |
Fair Value, Inputs, Level 2 [Member] | Convertible Debt Securities [Member] | ||
Assets | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 0 | |
Fair Value, Inputs, Level 3 [Member] | ||
Assets | 2,110 | 1,000 |
Liabilities | 2,300 | 41,516 |
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | 386 | |
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member] | ||
Liabilities | 1,914 | 39,602 |
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member] | ||
Assets | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | Restricted Cash Held in Escrow [Member] | ||
Assets | 0 | |
Fair Value, Inputs, Level 3 [Member] | Convertible Debt Securities [Member] | ||
Assets | $ 2,110 | 1,000 |
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member] | ||
Liabilities | $ 1,914 |
Note 2 - Fair Value Measureme_5
Note 2 - Fair Value Measurement - Fair Value of Assets Using Level 3 Input (Details) - Investments [Member] - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Balance, beginning of period | $ 1,000 | $ 0 | $ 1,000 | $ 0 |
Purchases | 0 | 1,000 | 0 | 1,000 |
Change in fair value recognized in net income | 1,110 | 0 | 1,110 | 0 |
Balance, end of period | $ 2,110 | $ 1,000 | $ 2,110 | $ 1,000 |
Note 2 - Fair Value Measureme_6
Note 2 - Fair Value Measurement - Fair Value of Liabilities Using Level 3 Input (Details) - Contingent Consideration Liabilities [Member] - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Balance, beginning of period | $ 388 | $ 1,492 | $ 1,914 | $ 0 |
Additions | 0 | 0 | 0 | 1,492 |
Change in fair value recognized in net income | (2) | 0 | (1,528) | 0 |
Payments earned, reclassified to accrued liabilities | 0 | 0 | 0 | 0 |
Balance, end of period | $ 386 | $ 1,492 | $ 386 | $ 1,492 |
Note 2 - Fair Value Measureme_7
Note 2 - Fair Value Measurement - Fair Value of Warrant Liabilities Using Level 3 Inputs (Details) - Warrant Liabilities [Member] - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Balance, beginning of period | $ 963 | $ 44,194 | $ 39,602 | $ 28,516 |
Exercised warrants | (54) | (1,295) | (33,221) | (1,694) |
Change in fair value recognized in net income | 1,005 | (1,128) | (4,467) | 14,949 |
Balance, end of period | $ 1,914 | $ 41,771 | $ 1,914 | $ 41,771 |
Note 3 - Acquisitions (Details
Note 3 - Acquisitions (Details Textual) - USD ($) | Nov. 12, 2019 | Aug. 08, 2019 | Apr. 01, 2019 | Sep. 30, 2020 | Jun. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | Nov. 11, 2019 | Aug. 07, 2019 | Mar. 31, 2019 |
Payment for Contingent Consideration Liability, Financing Activities | $ 483,000 | $ 0 | ||||||||||
Business Combination, Contingent Consideration, Liability, Total | $ 386,000 | $ 388,000 | 386,000 | |||||||||
Goodwill, Ending Balance | 33,506,000 | 33,506,000 | $ 33,637,000 | |||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 0 | 19,932,000 | ||||||||||
Equity Method Investments | 54,000 | 54,000 | ||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total | 0 | $ 10,108,000 | 0 | $ 10,108,000 | ||||||||
SAVSU [Member] | ||||||||||||
Equity Method Investments | $ 5,800,000 | |||||||||||
Astero [Member] | ||||||||||||
Payments to Acquire Businesses, Gross | $ 12,521,000 | |||||||||||
Payments to Acquire Businesses, Initial Cash Payment | 8,000,000 | |||||||||||
Payments to Acquire Businesses, Deferred Cash Payment | 4,500,000 | |||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | 1,491,000 | |||||||||||
Payment for Contingent Consideration Liability, Financing Activities | $ 483,000 | |||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 8,500,000 | |||||||||||
Business Combination, Contingent Consideration, Liability, Total | 1,500,000 | 80,000 | 80,000 | 1,100,000 | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Tangible Assets | 324,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets | 4,100,000 | |||||||||||
Goodwill, Ending Balance | 9,500,000 | $ 9,515,000 | ||||||||||
Business Acquisition, Goodwill, Expected Tax Deductible Amount | 1,100,000 | |||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 1,100,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 13,941,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 4,120,000 | |||||||||||
Astero [Member] | Earnout Payments Payable in Each Calendar Years of 2019, 2020 and 2021 [Member] | ||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | 3,500,000 | |||||||||||
Astero [Member] | Earnout Payment for Calendar Year 2021 [Member] | ||||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 5,000,000 | |||||||||||
SAVSU [Member] | ||||||||||||
Goodwill, Ending Balance | $ 19,500,000 | $ 21,037,000 | ||||||||||
Business Combinations, Number of Shares Acquired (in shares) | 8,616 | |||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 56.00% | |||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 1,100,000 | |||||||||||
Share Price (in dollars per share) | $ 18.12 | |||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 19,932,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 35,800,000 | $ 35,850,000 | ||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value | $ 15,900,000 | |||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage | 44.00% | |||||||||||
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total | $ 10,100,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net | 4,200,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 12,150,000 | |||||||||||
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination, Total | $ 35,800,000 | |||||||||||
CBS Acquisition [Member] | ||||||||||||
Payments to Acquire Businesses, Gross | $ 11,000,000 | |||||||||||
Payments to Acquire Businesses, Initial Cash Payment | 11,000,000 | |||||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | 856,000 | |||||||||||
Business Combination, Contingent Consideration, Liability, Total | $ 306,000 | $ 306,000 | $ 856,000 | |||||||||
Goodwill, Ending Balance | 3,100,000 | $ 2,954,000 | ||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 4,000,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | 15,856,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net | 6,000,000 | |||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 6,800,000 | $ 6,790,000 | ||||||||||
Business Combination, Consideration Transferred, Excluding Contingent Consideration | 15,000,000 | |||||||||||
Business Combination, Cash Holdback Escrow to Satisfy Indemnification Claims | 550,000 | |||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Escrow Holdback | 3,000,000 | |||||||||||
CBS Acquisition [Member] | Earning Payments Payable in Each Calendar Year 2020, 2021, 2022, 2023, and 2024 [Member] | ||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 15,000,000 |
Note 3 - Acquisitions - Conside
Note 3 - Acquisitions - Consideration (Details) - USD ($) $ in Thousands | Nov. 12, 2019 | Aug. 08, 2019 | Apr. 01, 2019 | Sep. 30, 2020 | Sep. 30, 2019 |
Stock consideration | $ 0 | $ 19,932 | |||
Astero [Member] | |||||
Cash consideration | $ 12,521 | ||||
Contingent consideration | 1,491 | ||||
Working capital adjustment | (71) | ||||
Total consideration transferred | $ 13,941 | ||||
SAVSU [Member] | |||||
Stock consideration | $ 19,932 | ||||
CBS Acquisition [Member] | |||||
Cash consideration | $ 11,000 | ||||
Contingent consideration | 856 | ||||
Total consideration transferred | 15,856 | ||||
Stock consideration | $ 4,000 |
Note 3 - Acquisitions - Consi_2
Note 3 - Acquisitions - Consideration (Details) (Parentheticals) | Aug. 08, 2019 |
SAVSU [Member] | |
Percentage equity interest purchased | 56.00% |
Note 3 - Acquisitions - Fair Va
Note 3 - Acquisitions - Fair Value of Net Assets Acquired (Details) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 | Nov. 12, 2019 | Nov. 11, 2019 | Aug. 08, 2019 | Aug. 07, 2019 | Apr. 01, 2019 | Mar. 31, 2019 |
Goodwill | $ 33,506,000 | $ 33,637,000 | ||||||
Astero [Member] | ||||||||
Cash and cash equivalents | $ 11,000 | |||||||
Accounts receivable, net | 154,000 | |||||||
Inventory | 456,000 | |||||||
Intangible assets | $ 4,120,000 | |||||||
Goodwill | 9,500,000 | 9,515,000 | ||||||
Other assets | 99,000 | |||||||
Accounts payable | (250,000) | |||||||
Other liabilities | 164,000 | |||||||
Fair value of net assets acquired | 13,941,000 | |||||||
Other liabilities | (164,000) | |||||||
Fair value of net assets acquired | 13,941,000 | |||||||
Inventory | 456,000 | |||||||
Astero [Member] | Customer Relationships [Member] | ||||||||
Intangible assets | 160,000 | 160,000 | ||||||
Astero [Member] | Trade Names [Member] | ||||||||
Intangible assets | 470,000 | 470,000 | ||||||
Astero [Member] | Developed Technology Rights [Member] | ||||||||
Intangible assets | 2,840,000 | 2,840,000 | ||||||
Astero [Member] | In Process Research and Development [Member] | ||||||||
Intangible assets | $ 650,000 | $ 650,000 | ||||||
SAVSU [Member] | ||||||||
Cash and cash equivalents | $ 1,251,000 | |||||||
Accounts receivable, net | 753,000 | |||||||
Intangible assets | $ 12,150,000 | |||||||
Goodwill | 19,500,000 | 21,037,000 | ||||||
Accounts payable | (807,000) | |||||||
Other liabilities | 232,000 | |||||||
Fair value of net assets acquired | 35,800,000 | 35,850,000 | ||||||
Prepaid expenses and other current assets | 19,000 | |||||||
Property, plant and equipment, net | 546,000 | |||||||
Operating right-of-use asset | 233,000 | 233,000 | ||||||
Assets held for rent, net | 2,441,000 | |||||||
Deferred tax liabilities | (1,541,000) | |||||||
Other liabilities | (232,000) | |||||||
Fair value of net assets acquired | 35,800,000 | 35,850,000 | ||||||
SAVSU [Member] | Customer Relationships [Member] | ||||||||
Intangible assets | 80,000 | 80,000 | ||||||
SAVSU [Member] | Trade Names [Member] | ||||||||
Intangible assets | $ 1,320,000 | 1,320,000 | ||||||
SAVSU [Member] | Developed Technology Rights [Member] | ||||||||
Intangible assets | $ 10,750,000 | |||||||
CBS Acquisition [Member] | ||||||||
Accounts receivable, net | $ 1,044,000 | |||||||
Inventory | 3,232,000 | |||||||
Intangible assets | $ 6,800,000 | 6,790,000 | ||||||
Goodwill | $ 3,100,000 | 2,954,000 | ||||||
Accounts payable | (1,197,000) | |||||||
Other liabilities | 611,000 | |||||||
Fair value of net assets acquired | 15,856,000 | |||||||
Prepaid expenses and other current assets | 29,000 | |||||||
Property, plant and equipment, net | 3,615,000 | |||||||
Other liabilities | (611,000) | |||||||
Fair value of net assets acquired | 15,856,000 | |||||||
Inventory | 3,232,000 | |||||||
CBS Acquisition [Member] | Customer Relationships [Member] | ||||||||
Intangible assets | 560,000 | |||||||
CBS Acquisition [Member] | Trade Names [Member] | ||||||||
Intangible assets | 800,000 | |||||||
CBS Acquisition [Member] | Developed Technology Rights [Member] | ||||||||
Intangible assets | $ 5,430,000 |
Note 3 - Acquisitions - Acquire
Note 3 - Acquisitions - Acquired Intangible Assets (Details) - USD ($) $ in Thousands | Nov. 11, 2019 | Aug. 08, 2019 | Apr. 01, 2019 | Sep. 30, 2020 | Nov. 12, 2019 | Aug. 07, 2019 | Mar. 31, 2019 |
Intangible assets, estimated useful life (Year) | 9 years | ||||||
Astero [Member] | |||||||
Intangible assets | $ 4,120 | ||||||
Astero [Member] | Customer Relationships [Member] | |||||||
Intangible assets | $ 160 | $ 160 | |||||
Intangible assets, estimated useful life (Year) | 4 years | ||||||
Astero [Member] | Trade Names [Member] | |||||||
Intangible assets | $ 470 | 470 | |||||
Intangible assets, estimated useful life (Year) | 9 years | ||||||
Astero [Member] | Developed Technology Rights [Member] | |||||||
Intangible assets | $ 2,840 | 2,840 | |||||
Astero [Member] | Developed Technology Rights [Member] | Minimum [Member] | |||||||
Intangible assets, estimated useful life (Year) | 5 years | ||||||
Astero [Member] | Developed Technology Rights [Member] | Maximum [Member] | |||||||
Intangible assets, estimated useful life (Year) | 9 years | ||||||
Astero [Member] | In Process Research and Development [Member] | |||||||
Intangible assets | $ 650 | $ 650 | |||||
Intangible assets, estimated useful life (Year) | 9 years | ||||||
SAVSU [Member] | |||||||
Intangible assets | $ 12,150 | ||||||
SAVSU [Member] | Customer Relationships [Member] | |||||||
Intangible assets | $ 80 | $ 80 | |||||
Intangible assets, estimated useful life (Year) | 6 years | ||||||
SAVSU [Member] | Trade Names [Member] | |||||||
Intangible assets | $ 1,320 | 1,320 | |||||
Intangible assets, estimated useful life (Year) | 9 years | ||||||
SAVSU [Member] | Developed Technology Rights [Member] | |||||||
Intangible assets | $ 10,750 | ||||||
SAVSU [Member] | Technology-Based Intangible Assets [Member] | |||||||
Intangible assets | $ 10,750 | ||||||
SAVSU [Member] | Technology-Based Intangible Assets [Member] | Minimum [Member] | |||||||
Intangible assets, estimated useful life (Year) | 7 years | ||||||
SAVSU [Member] | Technology-Based Intangible Assets [Member] | Maximum [Member] | |||||||
Intangible assets, estimated useful life (Year) | 8 years | ||||||
CBS Acquisition [Member] | |||||||
Intangible assets | $ 6,790 | $ 6,800 | |||||
CBS Acquisition [Member] | Customer Relationships [Member] | |||||||
Intangible assets | $ 560 | ||||||
Intangible assets, estimated useful life (Year) | 6 years | ||||||
CBS Acquisition [Member] | Trade Names [Member] | |||||||
Intangible assets | $ 800 | ||||||
Intangible assets, estimated useful life (Year) | 6 years | ||||||
CBS Acquisition [Member] | Developed Technology Rights [Member] | |||||||
Intangible assets | $ 5,430 | ||||||
Intangible assets, estimated useful life (Year) | 9 years |
Note 4 - Inventory - Summary of
Note 4 - Inventory - Summary of Inventories (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Raw materials | $ 2,731 | $ 2,979 |
Work in progress | 2,252 | 1,896 |
Finished goods | 6,054 | 6,097 |
Total | $ 11,037 | $ 10,972 |
Note 5 - Assets Held for Rent_2
Note 5 - Assets Held for Rent (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Assets Held for Rent, Depreciation | $ 186,000 | $ 51,000 | $ 581,000 | $ 51,000 |
Note 5 - Assets Held for Rent -
Note 5 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Shippers placed in service | $ 4,666 | $ 3,073 |
Accumulated deprecation | (755) | (174) |
Net | 3,911 | 2,899 |
Shippers and related components in production | 1,220 | 1,023 |
Total | $ 5,131 | $ 3,922 |
Note 6 - Goodwill and Intangi_3
Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($) | Apr. 01, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 |
Goodwill, Purchase Accounting Adjustments | $ (131,000) | ||||
Increase (Decrease) in Accounts Payable, Total | (604,000) | $ 377,000 | |||
Amortization of Intangible Assets, Total | $ 706,000 | $ 361,000 | $ 2,100,000 | $ 465,000 | |
Finite-Lived Intangible Asset, Useful Life (Year) | 9 years | ||||
In Process Research and Development [Member] | |||||
Finite-Lived Intangible Assets, Period Increase (Decrease), Total | $ (650,000) | ||||
CBS Acquisition [Member] | Immaterial Error [Member] | |||||
Goodwill, Purchase Accounting Adjustments | $ (131,000) | ||||
Increase (Decrease) in Accounts Payable, Total | $ (131,000) |
Note 6 - Goodwill and Intangi_4
Note 6 - Goodwill and Intangible Assets - Goodwill (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2020USD ($) | |
Balance | $ 33,637 |
Correction of an error related to CBS goodwill | (131) |
Balance | $ 33,506 |
Note 6 - Goodwill and Intangi_5
Note 6 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2020 | Dec. 31, 2019 | |||
Gross Carrying Value | $ 23,060 | $ 23,060 | ||
Accumulated Amortization | (3,179) | (1,078) | ||
Net Carrying Value | $ 19,881 | $ 21,982 | ||
Weighted Average Useful Life (Year) | 9 years | |||
Weighted Average [Member] | ||||
Weighted Average Useful Life (Year) | 7 years 2 months 12 days | 8 years 3 months 18 days | ||
Customer Relationships [Member] | ||||
Gross Carrying Value | $ 800 | $ 800 | ||
Accumulated Amortization | (161) | (51) | ||
Net Carrying Value | $ 639 | $ 749 | ||
Customer Relationships [Member] | Weighted Average [Member] | ||||
Weighted Average Useful Life (Year) | 4 years 6 months | 5 years 7 months 6 days | ||
Trade Names [Member] | ||||
Gross Carrying Value | $ 2,590 | $ 2,590 | ||
Accumulated Amortization | (372) | (123) | ||
Net Carrying Value | $ 2,218 | $ 2,467 | ||
Trade Names [Member] | Weighted Average [Member] | ||||
Weighted Average Useful Life (Year) | 6 years 10 months 24 days | 8 years 1 month 6 days | ||
Technology-Based Intangible Assets [Member] | ||||
Gross Carrying Value | $ 19,670 | [1] | $ 19,020 | |
Accumulated Amortization | (2,646) | (904) | ||
Net Carrying Value | $ 17,024 | [1] | $ 18,116 | |
Technology-Based Intangible Assets [Member] | Weighted Average [Member] | ||||
Weighted Average Useful Life (Year) | 7 years 3 months 18 days | 8 years 4 months 24 days | ||
In Process Research and Development [Member] | ||||
Gross Carrying Value | [2] | $ 650 | ||
Accumulated Amortization | [2] | 0 | ||
Net Carrying Value | [2] | $ 650 | ||
In Process Research and Development [Member] | Weighted Average [Member] | ||||
Weighted Average Useful Life (Year) | [2] | 9 years | ||
[1] | We transferred $650,000 out of “in-process R&D” into “Technology - acquired” on April 1, 2020, which was the date on which the product line became technologically feasible. | |||
[2] | In-process R&D represents the fair value of incomplete research and development that has not yet reached technological feasibility. On April 1, 2020, we began amortizing the asset since it reached technological feasibility (see footnote 1 above). |
Note 6 - Goodwill and Intangi_6
Note 6 - Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
2020 (3 months remaining) | $ 705 | |
2021 | 2,825 | |
2022 | 2,825 | |
2023 | 2,795 | |
2024 | 2,770 | |
Thereafter | 7,961 | |
Total | $ 19,881 | $ 21,982 |
Note 7 - Share-based Compensa_3
Note 7 - Share-based Compensation (Details Textual) - USD ($) | Mar. 25, 2020 | Apr. 01, 2019 | Feb. 25, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 |
Share-based Payment Arrangement, Expense | $ 1,560,000 | $ 829,000 | $ 3,818,000 | $ 2,179,000 | |||
Share-based Payment Arrangement, Option [Member] | |||||||
Share-based Payment Arrangement, Expense | 15,000 | 65,000 | 104,000 | 305,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | 28,600,000 | 28,600,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | 28,100,000 | 28,100,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | 2,200,000 | 1,700,000 | $ 6,800,000 | $ 5,200,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 3 years 9 months 18 days | ||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 43,000 | $ 43,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year | ||||||
Performance Shares [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||||||
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | 19,700,000 | $ 19,700,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 0 | $ 2,300,000 | $ 239,000 | $ 2,300,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | 0 | 0 | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 2 months 12 days | ||||||
Restricted Stock [Member] | |||||||
Share-based Payment Arrangement, Expense | $ 754,000 | $ 303,000 | $ 1,600,000 | $ 826,000 | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 10,000,000 | $ 10,000,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 3 years 3 months 18 days | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value | 4,200,000 | 802,000,000,000 | $ 7,400,000 | 4,000,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | 1,600,000 | 368,000 | $ 2,900,000 | 1,600,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 448,267 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 15.78 | ||||||
Restricted Stock [Member] | Executive Officer [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 34,154 | 34,154 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 9.18 | $ 9.18 | |||||
Performance-based Restricted Stock [Member] | |||||||
Share-based Payment Arrangement, Expense | 191,000 | $ 569,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 191,000 | $ 191,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 3 months 18 days | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 82,805 | 82,805 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 9.18 | $ 9.18 | |||||
Performance-based Restricted Stock [Member] | Minimum [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 0.00% | ||||||
Performance-based Restricted Stock [Member] | Maximum [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 125.00% | ||||||
Market-based Restricted Stock [Member] | |||||||
Share-based Payment Arrangement, Expense | 600,000 | $ 461,000 | $ 1,500,000 | $ 1,000,000 | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 1,300,000 | $ 1,300,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 10 months 24 days | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 109,140 | 29,604 | 94,247 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | 78.00% | 69.00% | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 0.30% | 2.50% | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 2 years | 2 years | |||||
Market-based Restricted Stock [Member] | Minimum [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 0.00% | 0.00% | |||||
Market-based Restricted Stock [Member] | Maximum [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards | 200.00% | 200.00% |
Note 7 - Share-based Compensa_4
Note 7 - Share-based Compensation - Stock Option Activity (Details) | 9 Months Ended | |
Sep. 30, 2020$ / sharesshares | Sep. 30, 2019shares | |
Share-based Payment Arrangement, Option [Member] | ||
Outstanding (in shares) | shares | 1,570,455 | |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 1.96 | |
Granted (in shares) | shares | 0 | 0 |
Granted, weighted average exercise price (in dollars per share) | $ / shares | $ 0 | |
Exercised (in shares) | shares | (511,680) | |
Exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 1.95 | |
Forfeited (in shares) | shares | 0 | |
Forfeited, weighted average exercise price (in dollars per share) | $ / shares | $ 0 | |
Expired (in shares) | shares | 0 | |
Expired, weighted average exercise price (in dollars per share) | $ / shares | $ 0 | |
Outstanding (in shares) | shares | 1,058,775 | |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 1.96 | |
Options exercisable (in shares) | shares | 1,039,399 | |
Options exercisable, weighted average exercise price (in dollars per share) | $ / shares | $ 1.94 | |
Performance Shares [Member] | ||
Outstanding (in shares) | shares | 737,497 | |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 1.64 | |
Granted (in shares) | shares | 0 | |
Granted, weighted average exercise price (in dollars per share) | $ / shares | $ 0 | |
Exercised (in shares) | shares | (17,113) | |
Exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 1.64 | |
Outstanding (in shares) | shares | 720,384 | |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 1.64 | |
Options exercisable (in shares) | shares | 720,384 | |
Options exercisable, weighted average exercise price (in dollars per share) | $ / shares | $ 1.64 |
Note 7 - Share-based Compensa_5
Note 7 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares | Mar. 25, 2020 | Sep. 30, 2020 |
Restricted Stock [Member] | ||
Outstanding (in shares) | 429,399 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 448,267 | |
Vested (in shares) | (161,263) | |
Forfeited (in shares) | (24,861) | |
Expected to vest (in shares) | 448,267 | |
Outstanding (in shares) | 725,696 | |
Outstanding (in dollars per share) | $ 13.25 | |
Granted, grant date fair value (in dollars per share) | 15.78 | |
Vested, grant date fair value (in dollars per share) | 11.12 | |
Forfeited, grant date fair value (in dollars per share) | 14.80 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | 15.78 | |
Outstanding (in dollars per share) | $ 15.04 | |
Restricted Stock [Member] | Executive Officer [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 34,154 | 34,154 |
Expected to vest (in shares) | 34,154 | 34,154 |
Granted, grant date fair value (in dollars per share) | $ 9.18 | $ 9.18 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 9.18 | $ 9.18 |
Performance-based Restricted Stock [Member] | ||
Outstanding (in shares) | 0 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 82,805 | 82,805 |
Vested (in shares) | 0 | |
Forfeited (in shares) | 0 | |
Expected to vest (in shares) | 82,805 | 82,805 |
Outstanding (in shares) | 82,805 | |
Outstanding (in dollars per share) | $ 0 | |
Granted, grant date fair value (in dollars per share) | $ 9.18 | 9.18 |
Vested, grant date fair value (in dollars per share) | 0 | |
Forfeited, grant date fair value (in dollars per share) | 0 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 9.18 | 9.18 |
Outstanding (in dollars per share) | $ 9.18 |
Note 7 - Share-based Compensa_6
Note 7 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Stock compensation expense | $ 1,560 | $ 829 | $ 3,818 | $ 2,179 |
Research and Development Expense [Member] | ||||
Stock compensation expense | 291 | 165 | 687 | 400 |
Selling and Marketing Expense [Member] | ||||
Stock compensation expense | 256 | 182 | 581 | 507 |
General and Administrative Expense [Member] | ||||
Stock compensation expense | 868 | 429 | 2,144 | 1,145 |
Cost of Sales [Member] | ||||
Stock compensation expense | $ 145 | $ 53 | $ 406 | $ 127 |
Note 8 - Warrants (Details Text
Note 8 - Warrants (Details Textual) - USD ($) | May 14, 2020 | Sep. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | May 31, 2016 | Mar. 31, 2014 |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4.75 | $ 4.75 | $ 4.33 | ||||
Class of Warrant or Right, Exercised During Period (in shares) | 3,879,905 | ||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 4.33 | ||||||
Proceeds from Warrant Exercises | $ 40,000 | $ 553,000 | |||||
Warrants to Purchase Common Stock [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,910,283 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4.75 | ||||||
Warrants in Connection with WAVI Credit Facility [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 550,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.75 | ||||||
WAVI Holding AG and Taurus4757 GmbH Warrants [Member] | |||||||
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares) | 2,747,970 | ||||||
Class of Warrant or Right, Exercised During Period (in shares) | 3,871,405 | 3,871,405 | |||||
Warrants Expiring March 2021 [Member] | |||||||
Class of Warrant or Right, Exercised During Period (in shares) | 3,500 | 8,500 | |||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 4.75 | $ 4.75 | |||||
Proceeds from Warrant Exercises | $ 17,000 | $ 40,000 |
Note 8 - Warrants - Summary of
Note 8 - Warrants - Summary of Warrant Activity (Details) | 9 Months Ended |
Sep. 30, 2020$ / sharesshares | |
Outstanding, number of shares (in shares) | shares | 3,959,005 |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 4.33 |
Exercised, number of shares (in shares) | shares | (3,879,905) |
Exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 4.33 |
Outstanding, number of shares (in shares) | shares | 79,100 |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 4.75 |
Note 10 - Net Income (Loss) P_3
Note 10 - Net Income (Loss) Per Common Share (Details Textual) - shares | 3 Months Ended | 9 Months Ended |
Sep. 30, 2020 | Sep. 30, 2019 | |
Share-based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 1,900,000 | 2,500,000 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 63,000 | 3 |
Share-based Payment Arrangement [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 286,000 | 146,000 |
Note 10 - Net Income (Loss) P_4
Note 10 - Net Income (Loss) Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Net income (loss) | $ (1,133) | $ 10,269 | $ 4,795 | $ (4,640) |
Amount attributable to unvested restricted shares | 0 | (207) | (138) | 0 |
Amount attributable to warrants outstanding | 0 | (1,682) | (335) | 0 |
Net income (loss) allocated to common shareholders | $ (1,133) | $ 8,380 | $ 4,322 | $ (4,640) |
Basic (in shares) | 31,639,420 | 19,735,364 | 25,418,375 | 19,071,722 |
Basic earnings (loss) per common share (in dollars per share) | $ (0.04) | $ 0.42 | $ 0.17 | $ (0.24) |
Amount attributable to non-participating warrants | $ 0 | $ 279 | $ 49 | $ 0 |
Less: gain related to change in fair value of warrants | 0 | 1,128 | 4,467 | 0 |
Diluted net income (loss) allocated to common shareholders | $ (1,133) | $ 8,862 | $ 279 | $ (4,640) |
Warrants (in shares) | 0 | 3,046,363 | 1,954,137 | 0 |
Diluted weighted-average shares issued and outstanding (in shares) | 31,639,420 | 25,343,112 | 29,412,538 | 19,071,722 |
Diluted earnings (loss) per common share (in dollars per share) | $ (0.04) | $ 0.35 | $ 0.01 | $ (0.24) |
Share-based Payment Arrangement, Option [Member] | ||||
Share-based payment arrangements (in shares) | 0 | 2,420,884 | 1,754,051 | 0 |
Restricted Stock [Member] | ||||
Share-based payment arrangements (in shares) | 0 | 140,501 | 285,975 | 0 |
Note 12 - Revenue - Revenues by
Note 12 - Revenue - Revenues by Product Line (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Total revenue | $ 11,279 | $ 6,604 | $ 33,361 | $ 19,075 |
Biopreservation Media [Member] | ||||
Total revenue | 7,414 | 6,069 | 22,753 | 18,165 |
Automated Thawing Products [Member] | ||||
Total revenue | 277 | 324 | 1,047 | 699 |
Evo Shippers [Member] | ||||
Total revenue | 494 | 211 | 1,372 | 211 |
Freezers and Accessories [Member] | ||||
Total revenue | $ 3,094 | $ 0 | $ 8,189 | $ 0 |
Note 13 - Leases (Details Textu
Note 13 - Leases (Details Textual) | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2020USD ($)ft²a | Sep. 30, 2019USD ($) | Sep. 30, 2020USD ($)ft²a | Sep. 30, 2019USD ($) | Dec. 31, 2019USD ($) | Aug. 08, 2019USD ($) | Aug. 07, 2019USD ($) | Jan. 01, 2019USD ($) | |
Operating Lease, Weighted Average Discount Rate, Percent | 6.50% | 6.50% | ||||||
Finance Lease, Weighted Average Discount Rate, Percent | 8.10% | 8.10% | ||||||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 1 year | 1 year | ||||||
Finance Lease, Weighted Average Remaining Lease Term (Year) | 4 months 24 days | 4 months 24 days | ||||||
Operating Lease, Right-of-Use Asset | $ 585,000 | $ 585,000 | $ 1,040,000 | $ 1,300,000 | ||||
Operating Lease, Liability, Total | 755,000 | 755,000 | $ 1,800,000 | |||||
Lease Cost, Operating Leases | 229,000 | 685,000 | ||||||
Operating Lease, Cost | 170,000 | 509,000 | ||||||
Short-term Lease, Cost | 59,000 | 176,000 | ||||||
Variable Lease, Cost | 0 | 0 | ||||||
Operating Lease, Payments | $ 219,000 | $ 653,000 | ||||||
Operating Lease, Expense | $ 160,000 | $ 444,000 | ||||||
SAVSU [Member] | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Asset | $ 233,000 | $ 233,000 | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability | $ 232,000 | |||||||
Bothell, Washington Headquarters [Member] | ||||||||
Area of Real Estate Property (Square Foot) | ft² | 32,106 | 32,106 | ||||||
Lessee, Operating Lease, Renewal Term (Year) | 5 years | 5 years | ||||||
Monthly Base Rent Expense | $ 63,000 | |||||||
Menlo Park, California Location [Member] | ||||||||
Area of Real Estate Property (Square Foot) | ft² | 1,250 | 1,250 | ||||||
Monthly Base Rent Expense | $ 5,000 | |||||||
Albuquerque, New Mexico Location [Member] | ||||||||
Area of Real Estate Property (Square Foot) | ft² | 9,932 | 9,932 | ||||||
Lessee, Operating Lease, Renewal Term (Year) | 3 years | 3 years | ||||||
Monthly Base Rent Expense | $ 9,000 | |||||||
Detroit, Michigan Location [Member] | ||||||||
Area of Real Estate Property (Square Foot) | a | 106,998 | 106,998 | ||||||
Lessee, Operating Lease, Renewal Term (Year) | 60 months | 60 months | ||||||
Monthly Base Rent Expense | $ 15,000 |
Note 13 - Leases - Maturities o
Note 13 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Jan. 01, 2019 |
2020, operating leases | $ 220 | |
2020, finance leases | 4 | |
2021, operating leases | 559 | |
2021, finance leases | 2 | |
Total operating lease payments | 779 | |
Total financing lease payments | 6 | |
Less: operating lease interest | (24) | |
Less: financing lease interest | (1) | |
Total present value of operating lease liabilities | 755 | $ 1,800 |
Total present value of financing lease liabilities | $ 5 |
Note 14 - Condensed Consolida_3
Note 14 - Condensed Consolidated Balance Sheet Detail (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Depreciation, Total | $ 296,000 | $ 114,000 | $ 873,000 | $ 322,000 |
Note 14 - Condensed Consolida_4
Note 14 - Condensed Consolidated Balance Sheet Detail - Property and Equipment (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Property and equipment | $ 8,679 | $ 8,093 |
Less: Accumulated depreciation | (3,379) | (2,521) |
Net property and equipment | 5,300 | 5,572 |
Leasehold Improvements [Member] | ||
Property and equipment | 2,145 | 2,112 |
Furniture and Computer Equipment [Member] | ||
Property and equipment | 827 | 794 |
Manufacturing Facility [Member] | ||
Property and equipment | $ 5,707 | $ 5,187 |
Note 14 - Condensed Consolida_5
Note 14 - Condensed Consolidated Balance Sheet Detail - Accrued Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Accrued expenses and other current liabilities | $ 275 | $ 302 |
Other payables | 208 | 1,018 |
Accrued compensation | 2,538 | 1,554 |
Deferred revenue | 334 | 324 |
Other | 9 | 171 |
Total accrued expenses and other current liabilities | $ 3,364 | $ 3,369 |
Note 15 - Employee Benefit Pl_2
Note 15 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 100.00% | |||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 89,000 | $ 33,000 | $ 268,000 | $ 113,000 |
Note 16 - Subsequent Event (Det
Note 16 - Subsequent Event (Details Textual) - USD ($) | Oct. 01, 2020 | Jan. 31, 2021 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 |
Business Combination, Acquisition Related Costs | $ 179,000 | $ 291,000 | $ 417,000 | $ 538,000 | ||
SciSafe Holdings, Inc [Member] | ||||||
Business Combination, Acquisition Related Costs | $ 179,000 | |||||
SciSafe Holdings, Inc [Member] | Forecast [Member] | ||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 169,911 | |||||
SciSafe Holdings, Inc [Member] | Subsequent Event [Member] | ||||||
Payments to Acquire Businesses, Gross | $ 15,000,000 | |||||
Stock Issued During Period, Shares, Acquisitions (in shares) | 441,472 | |||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 611,383 | |||||
SciSafe Holdings, Inc [Member] | Subsequent Event [Member] | Maximum [Member] | ||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 626,000 |